Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorect…
Biotechnology
US, Cambridge [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Immuneering Corporation can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDImmuneering Corporation can't present revenue by segment